Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 1362

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 1362
---
 Company and require no consequential continuing involvement on the part of the Company are recognized as revenue
when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverables are delivered.
Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity
relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded
drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the
technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are
separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s
continued involvement is required, through research and development services that are related to its proprietary know-how and expertise
of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the
period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.

    F-22

Revenue disaggregated by revenue source for the years
ended December 31, 2024 and 2023, consists of the following:

 SCHEDULE OF DISAGGREGATED REVENUE  

    2024  
    2023 

    For the Years Ended December 31, 

    2024  
    2023 
  
    Product sales, net 
    $198,619,000  
    $117,447,000 
  
    Transfer of acquired product sales/profits 
     995,000  
     12,746,000 
  
    Total revenues 
    $199,614,000  
    $130,193,000 

Deferred revenue and customer deposits at December
31, 2024 and 2023, were $44,000 and $75,000, respectively. All deferred revenue and customer deposit amounts at December 31, 2023 were
recognized as revenue during the year ended December 31, 2024.

NOTE 4. RECENT PRODUCT ACQUISITIONS AND LICENSES

Acquisition of VEVYETM U.S. and Canadian Commercial
Rights

In July 2023, the Company acquired commercial rights
of VEVYE (cyclosporine ophthalmic solution) 0.